A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) plus /- nab-paclitaxel in patients with pancreatic cancer.

被引：10

作者：

Hidalgo, Manuel

Cooray, Prasad

Carrato, Alfredo

Jameson, Michael B.

Parnis, Francis

Jeffery, Mark

Grimison, Peter S.

Stagg, Robert J.

Holmgren, Eric

Kapoun, Ann M.

Dupont, Jakob

Tebbutt, Niall C.

机构：

[1] Ctr Integral Oncol Clara Campal, Madrid, Spain

[2] Monash Univ, Eastern Hlth Dept Med Oncol, Melbourne, Vic 3004, Australia

[3] Ramon Y Cajal Univ Hosp, Dept Med Oncol, Madrid, Spain

[4] Waikato Hosp, Hamilton, New Zealand

[5] Adelaide Canc Ctr, Adelaide, SA, Australia

[6] Christchurch Hosp, Christchurch, New Zealand

[7] Chris OBrien Lifehouse, Sydney, NSW, Australia

[8] Oncomed, Redwood City, CA USA

[9] Oncomed Pharmaceut, Redwood City, CA USA

[10] OncoMed Pharmaceut Inc, Redwood City, CA USA

[11] Austin Hlth, Melbourne, Vic, Australia

来源：

关键词：

D O I：

10.1200/jco.2016.34.4_suppl.341

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

341

引用

页数：1